Chen Haiming, Ma Yi, Liu Zheng, Li Jiawei, Li Xiao, Yang Fan, Qiu Mantang
Department of Thoracic Surgery, Peking University People's Hospital, Beijing, 100044, China.
Department of Thoracic Surgery, Peking University People's Hospital, Beijing, 100044, China.
Cancer Lett. 2021 Aug 28;521:82-87. doi: 10.1016/j.canlet.2021.08.036.
Dysbiosis of the human microbiome has long been reported to be closely associated with various cancers. Accumulating studies have shown that microbial dysbiosis can accelerate tumorigenesis through tumor-promoting inflammation, DNA damage, and inducing immune evasion. Differential composition of microbiome could be novel biomarkers for cancer detection or biomarkers of successful immunotherapy. More importantly, emerging evidence demonstrates that alterations of circulating microbiome DNA (cmDNA) could serve as promising noninvasive biomarkers for cancer detection. It has been reported that distinct circulating bacterial DNA could distinguish prostate cancer, lung cancer, and melanoma patients from healthy populations. Therefore, in this review, we summarized current literature on microbial biomarkers for cancer detection and unraveled the potential of cmDNA as a promising cancer detection tool.
长期以来，人们一直报道人类微生物群失调与各种癌症密切相关。越来越多的研究表明，微生物失调可通过促进肿瘤的炎症、DNA损伤和诱导免疫逃逸来加速肿瘤发生。微生物群的差异组成可能是癌症检测的新型生物标志物或成功免疫治疗的生物标志物。更重要的是，新出现的证据表明，循环微生物群DNA（cmDNA）的改变可作为有前景的癌症检测非侵入性生物标志物。据报道，不同的循环细菌DNA可以区分前列腺癌、肺癌和黑色素瘤患者与健康人群。因此，在本综述中，我们总结了关于癌症检测微生物生物标志物的当前文献，并揭示了cmDNA作为一种有前景的癌症检测工具的潜力。
